Veru lower after FDA reschedules advisory committee meeting

Shares of Veru are down $3.66, or 26%, to $10.62 after the FDA announced that a meeting of the Pulmonary-Allergy Drugs Advisory Committee has been rescheduled to be held virtually on November 9, from 9 a.m. to 5 p.m. Eastern Time. The meeting, which had previously been scheduled for October 6, will discuss the request for Emergency Use Authorization 113, for sabizabulin oral capsule, a tubulin polymerization inhibitor, submitted by Veru Inc., for the treatment of SARS- CoV-2 infection in moderate to severe COVID-19 infections at high risk of acute respiratory distress syndrome.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire